Haoxi Health Technology Limited Class A (HAO) AI Stock Analysis

• Market Cap: $28.84M
• Dividend Yield: N/A
• Average Volume (3M): 99.33K
• Price to Earnings (P/E): 114.3
• Beta (1Y): 1.19
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 30
• Sector: General
• Sector Strength: N/A
• Industry: Advertising Agencies
• EPS (TTM): 0.01
• Shares Outstanding: 2,131,595
• 10 Day Avg. Volume: 216,481
• 30 Day Avg. Volume: 99,330
• PEG Ratio: 35.95
• Price to Book (P/B): 3.79
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -35.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 55 Neutral
• Price Target: $1.50 ▼(-1.32%Downside)

The overall score reflects a balance of strong revenue growth and a solid equity position against challenges in cash flow generation and high valuation metrics. Short-term technical indicators are mildly positive, but long-term resistance and high P/E ratio contribute to a cautious outlook.

Haoxi Health Technology Limited Class A Business Overview & Revenue Model

Company Description

Haoxi Health Technology Limited, through its subsidiaries, provides online marketing solutions in China. It offers online marketing solutions, including online short video marketing solutions to advertisers through its media partners; and customized marketing solutions by planning, producing, placing, and optimizing online ads to help advertisers acquire, convert, and retain consumers on various online media platforms. The company places its ads through mainstream online short video and social media platforms, such as Toutiao, Douyin, WeChat, and Sina Weibo. It serves advertiser client base primarily in the healthcare industry. The company was founded in 2018 and is based in Beijing, China.

How the Company Makes Money

Haoxi Health Technology Limited generates revenue through multiple streams, primarily focusing on the sale and subscription of its digital health platforms and telemedicine services. The company offers subscription-based models for healthcare providers and patients to access its telemedicine platform, which facilitates virtual consultations and remote patient monitoring. Additionally, HAO earns revenue from the sale of its wearable health monitoring devices, which are marketed directly to consumers and through partnerships with healthcare institutions. Collaborations with insurance companies and healthcare providers also contribute to its earnings, enhancing the integration of its technology into existing healthcare systems.

Haoxi Health Technology Limited Class A Financial Statement Overview

Summary

Haoxi Health Technology Limited displays significant revenue growth and profitability turnaround, with improving equity position and low leverage. However, challenges remain in terms of cash flow generation and profit margins. Overall, the company is on a positive trajectory but needs to enhance its cash flow management and profitability to sustain long-term growth.

Income Statement

Haoxi Health Technology Limited shows strong revenue growth with a substantial increase from $28.2M in 2023 to $48.5M in 2024, marking a growth rate of 71.88%. The gross profit margin in 2024 stands at 5.67%, indicating an improvement over previous years but still relatively low. The net profit margin for 2024 is 2.66%, demonstrating profitability but with room for improvement. EBIT and EBITDA margins are 3.54% and 3.68%, respectively, showing stability in earnings.

Balance Sheet

The company exhibits a solid equity position with a positive stockholders' equity of $11.27M in 2024, a significant turnaround from negative equity in earlier years. However, the debt-to-equity ratio is 0.11, indicating low leverage but also reflecting a cautious approach. The equity ratio is relatively strong at 72.69%, showcasing financial stability, though the overall asset base remains modest.

Cash Flow

Cash flow performance is mixed, with negative free cash flow of -$802,943 in 2024, although showing improvement from the previous year. The operating cash flow to net income ratio is -0.58, suggesting that operating activities are not yet fully supporting net income generation. Despite this, the company has improved its financing cash flow, indicating potential for future investments.

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement		Total Revenue
48.52M	28.23M	16.16M	12.85M
	Gross Profit
2.75M	2.06M	648.72K	605.58K
	EBIT
1.72M	1.20M	268.77K	330.55K
	EBITDA
1.79M	1.22M	271.77K	330.96K
	Net Income Common Stockholders
1.29M	969.75K	244.59K	304.06K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.66M	1.20M	293.51K	55.89K
	Total Assets
15.51M	4.46M	542.99K	2.81M
	Total Debt
1.20M	897.61K	505.40K	1.15M
	Net Debt
-5.45M	-305.59K	211.89K	1.09M
	Total Liabilities
4.23M	2.90M	2.01M	4.74M
	Stockholders Equity
11.27M	1.57M	-1.47M	-1.93M
Cash Flow		Free Cash Flow
-802.94K	-917.63K	―	2.65M
	Operating Cash Flow
-747.58K	-872.13K	-675.36K	2.65M
	Investing Cash Flow
-3.13M	-45.50K	―	―
	Financing Cash Flow
9.32M	1.80M	933.22K	-2.61M

Haoxi Health Technology Limited Class A Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.52
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HAO, the sentiment is Positive. The current price of 1.52 is above the 20-day moving average (MA) of 1.44, above the 50-day MA of 1.38, and below the 200-day MA of 14.58, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 53.71 is Neutral, neither overbought nor oversold. The STOCH value of 30.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HAO.

Haoxi Health Technology Limited Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	57 Neutral	$4.85B	20.06	-16.90%	5.21%	13.58%	-28.06%
HAO	55 Neutral	$28.84M	114.29	2.92%	―	―	―
WIMI	53 Neutral	$34.37M	6.89	8.21%	―	-8.74%	―
MCHX	53 Neutral	$70.24M	―	-16.55%	―	-2.67%	21.65%
INUV	48 Neutral	$57.92M	―	-34.39%	―	18.20%	50.14%
DRCT	40 Underperform	$9.88M	―	-320.07%	―	-69.54%	-19665.56%
FLNT	38 Underperform	$37.20M	―	-123.16%	―	-15.07%	33.40%